MAHSC has collaborated with a wide range of companies, of all sizes, on a diverse programme of work.
Below, some of these firms describe the benefits of working with our partners.
MAHSC is working with GlaxoSmithKline on the Salford Lung Study – a world-first in the use of real-world data:
“The Salford Lung Study, initiated on a pre-license medication for asthma and chronic obstructive pulmonary disease, is recognised as a world-first in its use of real-world data and would not have been possible without the collaboration between study sponsors GSK and MAHSC’s partners, including The University of Manchester, North-West E-Health, Salford Royal NHS Foundation Trust and Salford Clinical Commissioning Group’s local general practitioners and community pharmacists.”
AstraZeneca partnered with MAHSC and GlaxoSmithKline on the founding of the Manchester Collaborative Centre for Inflammation Research:
“The creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR) has offered AstraZeneca a unique opportunity to be at the forefront of translational medicine in a city internationally recognised for its expertise in inflammatory disease. The Centre allows us to work closely with some of the world’s leading inflammation researchers at the MCCIR and more broadly within The University of Manchester, which affords us a considerable advantage in terms of researching and developing cutting-edge treatments that may have a significant impact on the lives of patients across the globe.”
MAHSC signed a Memorandum of Understanding with pharmaceutical company Roche, the Greater Manchester Academic Health Science Network and the NIHR Greater Manchester Clinical Research Network in March 2014 to boost clinical research studies, which could lead to the development of new drugs and diagnostic tools and give patients in the region greater access to new treatments in development.
“Roche recognises the strong research community in Manchester and scientific potential of the UK – that’s why we’re excited to establish this collaborative relationship”
Christopher Burdette, Head of Project Strategy and Portfolio Management at Roche Products Limited
The Memorandum of Understanding between MAHSC, Hitachi, Eagle Matrix Consulting, NorthWest EHealth and the NHS in Greater Manchester, was signed in April 2013. The partners agreed to work together to plan and develop informatics technology to manage and improve patient care and population health.
“This partnership offers us the opportunity to contribute towards the enhancement of healthcare in the UK and eventually duplicate this model in other regions around the world”
Masaya Watanabe, Vice President and Executive Officer of Hitachi, Ltd., who is also the Chief Strategy Officer and Chief Innovation Officer of Hitachi’s Information and Telecommunication Systems Company
“[There is a] clear advantage in leveraging the synergies both in vision and technology between the Hitachi Group and the NHS in Manchester, where the wider health economy provides the ideal launch pad for innovative health services.”
Hiroshi Ashibe, President of Hitachi Consulting Co., Ltd
NICE renewed their three-year Memorandum of Understanding with MAHSC and The University of Manchester in June 2014. The three organisations made significant contributions to the assessment of new drugs and medical technologies and the development of treatment guidelines and quality standards after their initial partnership beginning in 2011.
“Our relationship has been a very fruitful one because of our shared commitments to using the very best science and evidence to improve the health of our population. Translating research into better patient care and training the healthcare professionals of tomorrow are vital in this endeavour, and I’m delighted that this partnership is making this happen. We look forward to many more years of successes.”
Sir Andrew Dillon, Chief Executive of NICE